Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial

Study limitation reported by the research below: “No brand name for sutetinib was reported in the paper; brand tag omitted.”